Oneness Biotech Co., Ltd. (4743.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$47.15 (-1.05%) as of
Key statistics
- Market cap
- 22.61B
- P/E (TTM)
- 362.69
- EPS (TTM)
- 0.13
- Dividend yield
- 0.00%
- 52-week range
- 40.80 – 76.70
- Beta
- 0.75
- Revenue (TTM)
- 153.78M
- Profit margin
- 39.55%
- Analyst target
- NT$308.00
- Volume
- 533.18k
About Oneness Biotech Co., Ltd.
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rheumatoid arthritis and inhibiting tumor angiogenesis; SNS812, which is in Phase II clinical trial for the treatment of COVID; and SNS851 which is in clinical development for potential applications in metabolic diseases such as obesity, diabetes, hypercholesterolemia, and fatty liver disease. In addition, the company is involved in the management of agriculture cultivation and organic food trading business; and sale of organic food, dietary supplements, and beverages. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.